J L Ruckle - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

J L Ruckle

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Postgraduate Medicine|March 1, 1989

Depression. Management techniques in primary careF W Silver, J L Ruckle

Journal of Child and Adolescent Psychopharmacology|June 5, 1999

A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adultsR Dixon, K Engleman, J Kemp, et al.

Clinical Pharmacology and Therapeutics|February 11, 2000

Pharmacokinetics of repaglinide in subjects with renal impairmentT C Marbury, J L Ruckle, V Hatorp, et al.

Antimicrobial Agents and Chemotherapy|April 17, 2001

Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjectsT Creagh, J L Ruckle, D T Tolbert, et al.

Pageof 1

Search research articles

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Postgraduate Medicine|March 1, 1989

Depression. Management techniques in primary careF W Silver, J L Ruckle

Journal of Child and Adolescent Psychopharmacology|June 5, 1999

A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adultsR Dixon, K Engleman, J Kemp, et al.

Clinical Pharmacology and Therapeutics|February 11, 2000

Pharmacokinetics of repaglinide in subjects with renal impairmentT C Marbury, J L Ruckle, V Hatorp, et al.

Antimicrobial Agents and Chemotherapy|April 17, 2001

Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjectsT Creagh, J L Ruckle, D T Tolbert, et al.

Pageof 1